Page 109 - 《中国药房》2023年11期
P. 109

注射用艾普拉唑钠的回顾性多中心巢式病例对照安全性研究
                                                                                                       Δ


                                                            6
                                                                                              2 #b
                                                                            8
                                                                    7
                                            4
                                                    5
                                    3
                           2
          李 晋    1, 2* ,方壬德 ,宋 娟 ,张永州 ,张 帆 ,赵 群 ,蔡素华 ,张 怡 ,胡海棠 ,邓剑雄 (1.广州和睦家
                                                                                     3 #a
          医院药剂科,广州 510335;2.广东省药理学会,广州 510080;3.丽珠医药集团股份有限公司,广东 珠海
          519000;4.河南大学淮河医院药剂科,河南 开封 475000;5.聊城市人民医院药剂科,山东 聊城 252000;6.淄
          博市中心医院药剂科,山东 淄博 255036;7.广州中医药大学金沙洲医院药剂科,广州 510168;8.东莞康华医
          院药剂科,广东 东莞 523080)
          中图分类号  R975;R969      文献标志码  A      文章编号  1001-0408(2023)11-1379-05
          DOI  10.6039/j.issn.1001-0408.2023.11.18
          摘  要  目的  了解注射用艾普拉唑钠在临床实际应用中的安全性。方法  通过中国医院药物警戒系统收集5家三级医院2019年
          1月1日至2020年2月29日使用注射用艾普拉唑钠的住院患者共3 926例的病历资料,采用回顾性多中心单队列研究对注射用艾
          普拉唑钠进行上市后安全性分析;同时采用巢式病例对照研究(试验组与对照组按1∶4比例匹配)来证实本研究队列基线的稳定
          性,以及不良反应与注射用艾普拉唑钠的相关性。结果  3 926例患者中,3例患者使用注射用艾普拉唑钠后共发生了5次不良事
          件,不良事件发生率为0.076%,无严重不良事件,发生时间均为用药2 d后;不良事件以肝功能指标(丙氨酸转氨酶、天冬氨酸转氨
          酶、总胆红素)升高为主,均为轻度且未处理,所有不良事件转归均为好转。巢式病例对照研究结果显示,试验组与对照组属于同
          一背景基线,不良事件的发生与注射用艾普拉唑钠相关性更大。结论  注射用艾普拉唑钠整体安全性较高,不良事件的发生与其
          相关性更大。
          关键词  注射用艾普拉唑钠;回顾性研究;巢式病例对照;安全性研究;药品不良反应;药品不良事件

          Retrospective multicenter nested case-control safety study of Ilaprazole sodium for injection
                                                                                                           8
                             2
                                                                                               7
               1, 2
                                                                        5
          LI Jin ,FANG Rende ,SONG Juan ,ZHANG Yongzhou ,ZHANG Fan ,ZHAO Qun ,CAI Suhua ,ZHANG Yi ,
                                                                                    6
                                         3
                                                           4
          HU Haitang ,DENG Jianxiong(1.  Dept.  of  Pharmacy,  Guangzhou  United  Family  Hospital,  Guangzhou  510335,
                                    2
                    3
          China;2. Guangdong Pharmacological Society, Guangzhou 510080, China;3. Lizhu Pharmaceutical Group Co.,
          Ltd.,  Guangdong  Zhuhai  519000,  China;4.  Dept.  of  Pharmacy,  Huaihe  Hospital  of  Henan  University,  Henan
          Kaifeng  475000,  China;5.  Dept.  of  Pharmacy,  Liaocheng  Municipal  People’s  Hospital,  Shandong  Liaocheng
          252000,  China;6.  Dept.  of  Pharmacy,  Zibo  Central  Hospital,  Shandong  Zibo  255036,  China;7.  Dept.  of
          Pharmacy,  Jinshazhou  Hospital  of  Guangzhou  University  of  Chinese  Medicine,  Guangzhou  510168,  China;
          8. Dept. of Pharmacy, Dongguan Kanghua Hospital, Guangdong Dongguan 523080, China)
          ABSTRACT   OBJECTIVE To understand the safety of Ilaprazole sodium for injection in clinical practice. METHODS From Jan.
          1st  2019  to  Feb.  29th  2020,  the  data  of  3  926  valid  hospitalized  patients  receiving  Ilaprazole  sodium  for  injection  were  collected
          prospectively  from  5  third-level  hospitals  through  CHPS,  and  the  post-marketing  safety  analysis  was  performed  by  using
          retrospective  multicenter  single  cohort  study.  At  the  same  time,  a  nested  case-control  study (the  ratio  of  trial  group  and  control
          group  was  1∶4)  was  used  to  confirm  the  baseline  stability  of  this  study  cohort  and  the  correlation  between  adverse  reactions  and
          Ilaprazole  sodium  for  injection.  RESULTS  Among  3  926  patients,  3  patients  experienced  5  adverse  drug  events  after  using
          Ilaprazole sodium for injection, with the incidence of 0.076%. There was no serious adverse event, and the occurrence time was 2
          days  after  medication;  adverse  drug  events  mainly  include  elevated  liver  function  indicators (alanine  transaminase,  aspartate
          transaminase, total bilirubin), which were mild and untreated, and all adverse drug events were improved. The results of the nested
          case-control study showed that the trial group and the control group belonged to the same background baseline, and the occurrence
                                                             of  adverse  drug  events  was  more  closely  related  to  Ilaprazole
             Δ 基金项目 广 东 省 药 理 学 会 专 项 研 究 基 金(No. GDPHARS-
                                                             sodium  for  injection.  CONCLUSIONS  The  overall  safety  of
          X20210002)
                                                             Ilaprazole  sodium  for  injection  is  relatively  high,  and  the
             *第一作者 副主任药师,博士。研究方向:临床药学与药物安全
                                                             occurrence of adverse events is more related to it.
          性。E-mail:lijin@gdyl.org                            KEYWORDS
             #a 通信作者 高级工程师。研究方向:药物研发与药物警戒。                                Ilaprazole  sodium  for  injection;  retrospective
          E-mail:huhaitang@livzon.com.cn                     study;  nested  case-control;  safety  study;  adverse  drug
                                                             reaction; adverse drug events
             #b 通信作者 副主任医师,博士。研究方向:药物警戒与大规模安
          全性。E-mail:dengjianxiong@gdyl.org


          中国药房  2023年第34卷第11期                                              China Pharmacy  2023 Vol. 34  No. 11    · 1379 ·
   104   105   106   107   108   109   110   111   112   113   114